Antimicrobial use and use of granulocyte colony-stimulating factor were unchanged between the study periods, so we infer from our results that the reduction in NF-associated admissions may be attributable to the use of NPIs and that NPIs may be beneficial in patients undergoing chemotherapy with a risk of neutropenia. The gene discussed is CSF3; the disease is neutropenia.